



**HAL**  
open science

## Specific guidelines requirements for clinical trials with Advanced Therapy Medicinal Products in the EU

Aurélie Mahalatchimy, Éloïse Gennet, Michael Morrison, Véronique Andrieu,  
Julie Veran, Florence Sabatier

### ► To cite this version:

Aurélie Mahalatchimy, Éloïse Gennet, Michael Morrison, Véronique Andrieu, Julie Veran, et al.. Specific guidelines requirements for clinical trials with Advanced Therapy Medicinal Products in the EU. European Society for Gene & Cell Therapy Congress 2022, Oct 2022, Edinburgh, United Kingdom. MARY ANN LIEBERT, 33 (23-24), pp.A197-A197, 2022. halshs-03901386

**HAL Id: halshs-03901386**

**<https://shs.hal.science/halshs-03901386>**

Submitted on 15 Dec 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# Specific guidelines requirements for clinical trials with Advanced Therapy Medicinal Products in the EU

Aurélie Mahalatchimy<sup>1</sup>, Eloïse Gennet<sup>2</sup>, Michael Morrison<sup>3</sup>, Véronique Andrieu<sup>4</sup>, Julie Véran<sup>5</sup>, Florence Sabatier<sup>6</sup>

<sup>1</sup> Permanent Researcher in law at the French National Centre for Scientific Research (CNRS, CR), Law Faculty, UMR 7318 DICE CERIC, CNRS, Aix-Marseille Univ., Toulon Univ., Aix-en-Provence, France; <sup>2</sup> Post-doctoral Researcher in Law, Law Faculty, UMR 7318 International, Comparative and European laws (DICE) CERIC, CNRS, Aix-Marseille Univ., Toulon Univ., Aix-en-Provence, France; <sup>3</sup> Senior Research Fellow in Social Sciences, Centre for Health Law and Emerging Technologies (HeLEX), Oxford Univ., UK; <sup>4</sup> Senior lecturer in Industrial Pharmacy and Pharmaceutical Regulation, Faculty of Pharmacy, Aix-Marseille Univ., Research Unit Microbes Evolution Phylogeny and Infection (MEPHI) Aix-Marseille Univ., IRD, France; <sup>5</sup> Responsible of Cell therapy/Advanced Therapy Medicinal Products' production at Marseille Public Hospital (AP-HM), Biotherapies Clinical Investigation Center, France; <sup>6</sup> Professor of Hematology and Biotherapy, Pharmaceutical Sciences Faculty, C2VN INSERM INRAe 1263 Aix-Marseille Univ., Director of the cell therapy research centre at Marseille Public Hospital (AP-HM), France. **Acknowledgements:** This work has been supported by ANR-funded I-BioLex project (ANR-20-CE26-0007-01, coord. A. Mahalatchimy). M. Morrison is funded by the Leverhulme Trust through grant no RPG-2017-330.

## INTRODUCTION

Advanced Therapy Medicinal Products (ATMPs), a European legal classification of medicinal products based on genes, cells and tissues, raise specific issues in the context of clinical trials (CT). Several normative instruments apply at the European level (see table opposite). The 2019 guidelines from the European Commission on Good Clinical Practice (GCP) both adapt the ICH E6 to ATMPs' characteristics and provide necessary additional measures. However, they are not exhaustive as they explain only some specificities of ATMPs and they remain complementary to the general rules. We will highlight the specific requirements for investigational ATMPs (ATIMPs) to reveal the particular challenges they are addressing and why these challenges warrant separate regulation in order to obtain CT' authorisation for ATIMPs and potentially for further marketing authorisation application (MAA).

Level	Text	General	ATMPs
Legal		Regulation 536/2014 on clinical trials	Regulation 1394/2007 on ATMPs
Regulatory guidelines		ICH E6 on GCP	Specific GCP

### Clinical trials design

- Study population**  
**ATMPs characteristics** > Subjects' risks & benefits, interpretable data
- Cohorts**  
**Limited manufacturing capacity** > Staggered treatment
- Comparators**  
**No active comparator** > Best standard of care, or intra-subject control
- Blinding**  
**Double blinding unethical/ unfeasible** > For subjects' where possible; blinded observers if unblinded investigator
- Placebo**  
**Invasive procedures** > No more than minimal risk/burden for control groups
- Dosing**  
**Identifying active cells; inactive particles with impact; dose variation of cells numbers; complex dosing** > For long-term effects, dose escalation & repeated dosing Or exploratory dose = therapeutic dose
- Trial end**  
**Potential need for long-term follow-up** > Clearly defined event marking trial end

### Monitoring

**Human origin of cells/tissues** >  
Traceability requirements/ long-term follow-up arrangements compliance;  
For ATIMPs accountability records kept at CT site, possible requirement of adaptation of study requirements' form, records reflecting ATMPs specificities

### Administration of out of specifications products

**Variability in ATMPs nature** >  
Exceptionally to avoid immediate significant hazard; manufacturer/ sponsor to provide risks evaluation; records of request kept in manufacturing site; relevant authority to be notified

## ATMPs Guidelines content and potential challenges targeted

### Non-clinical studies

**Safety: incompatibility between human & animal species** > Case by case assessment of non-clinical data

### Quality

- General considerations**  
**ATMPs characteristics** > Compliance with GMP for ATMPs
- Starting materials**  
**Variability** > Compliance with directives on blood and cells/tissues; Traceability system's with bidirectional tracking
- Storage, transport & handling conditions**  
**e.g., temperature, short-shelf life** > Timelines in trial records; Investigator's training
- Reconstitution before administration**  
**Potentially complex** > use of solvents and/or other materials?; Training
- Medical devices (MD)**  
**Combined ATIMP** > MD characteristics, performance and intended use + MD Regulation Compliance OR justification of MD suitability for intended use  
**MD used with ATIMP** > List of investigated MD; statement on CE-marked MD; MD characteristics, performance, intended use, and regulatory status

### Information in Investigator Brochure and Protocol

**Placebo:** Procedure's risk  
**Dosing:** For complex dosing ATMPs, adequate level of understanding & compliance by investigator and those involved in CT  
**End of trial:** how follow-up activities will be performed after end of trial

**Product information in IB:**

- product risks;
- previous/ concomitant (or required further treatments) potential impact;
- treatment failure risk;
- emerging issues

**Risk minimization measures:** Where appropriate, measures to protect CT subjects from identified risks:

**Quality:** reconstitution before administration: Description of Reconstitution

**Upstream interventions on subjects and administration procedures:** Detailed instructions, possibly in separate document available at site if attached as Annex

**Long-term follow-up general principles & remote follow-up:**

- Follow-up scheme & after trial follow-up activities;
- Detailed arrangements for remote conduct of follow-up;
- How to ensure collected data quality

### CT Safe conduct

- ATIMP Handling**  
**Infectious biological material** > Handling and disposal detailed instructions  
**Bacterial/viral vector with shedding potential** > Risks and precautionary measures for subject and/or caregivers  
**Risks for health care professionals** > Risk minimisation measures
- Risk minimization measures**  
**e.g. No sterility test result at product release; CT subject risk of cytokine release syndrome** > Mitigation measures; Information to Investigator on measures before treatment

### Long-term follow up

- General principles**  
**Safety profile not fully elucidated** > Duration of ATIMP biological activity; long term follow-up scheme; Length of observation period; relevance of other product bibliographic data; not required if low risk of delayed adverse events; monitoring of CT subject follow-up in MAA
- Remote follow-up**  
**e.g. distance from residence** > Gathering data process; Sponsor responsible for adverse events collection robust system; Writing of each party involved responsibilities; Collected data centralisation & availability for inspection at CT site
- Premature end or termination**  
Specificities where CT subjects will and foreseen long-term follow-up
- Patient card alerts**  
For CT subjects depending on ATMPs characteristics to inform treating physicians to facilitate medical care in case of emergency & reporting of adverse events

### Upstream intervention on subjects and administration procedures

- General**  
**In autologous setting, deviation from standard clinical practice** > Subject's risks + impact on product quality and safety;  
**Procedure complexity and novelty** > Adapted level of documentation; Training  
**Possible necessary sponsor presence during administration or in any upstream collection procedure** > justification
- Traceability**  
**If human origin Cells/ tissues** > Bidirectional traceability system (anonymous coding); 30 years data keeping; Role and responsibilities of manufacturer, sponsor and investigator & location of traceability records to be documented
- Retention of samples**  
**Materials' scarcity** > Autologous ATMPs and certain allogeneic ATMPs: justified not to keep samples; Possible sampling strategy adaptation;  
**Short shelf-life** > Shorter retention period; Manufacturer to consider conditions for prolonging shelf-life;  
**Samples cannot be kept** > Retained label Photographs or copies

### Protection of CT subjects

**Uncertainties, novelty...** >  
**Informed consent:** CT participant information on all risks, e.g., treatment failure, irreversible ATIMP nature...

### Safety reporting

**ATMPs characteristics > safety concerns** > Adapted reporting forms & data capture systems; List of safety issues; Sponsor to provide information/ training to investigator for adverse events reporting; Foreseen long-term follow-up to include reporting of adverse events

## CONCLUSION

Very useful ATMPs specific guidelines for clinical trials covering many different aspects and all currently identified challenges

Necessary case by case evaluation of the various aspects of ATIMPs clinical trials mainly due to variability of starting materials and specific characteristics of each ATMP. Various levels of justification and documentation to be provided for clinical trials authorization

→ Particularly relevant to engage in a pre-CT application meeting with regulatory agencies, such as the French National Agency (ANSM) as it is proposed in France

#### REFERENCES

- European Commission, Guideline on Good Clinical Practice specific to Advanced Therapy Medicinal Products, 10 October 2019, C(2019) 7140 final.
- European Commission, Guidelines of 22 November 2017 on Good Manufacturing Practice for Advanced Therapy Medicinal Products, C(2017) 7694.
- Directive 2002/98/EC of the European Parliament and of the Council of 27 January 2003 setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood components; OJ L 33, 8.2.2003, p. 30–40.
- Directive 2004/23/EC of the European Parliament and of the Council of 31 March 2004 on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells, OJ L 102, 7.4.2004, p. 48–58.